MX2009009758A - Formulacion farmaceutica topica. - Google Patents
Formulacion farmaceutica topica.Info
- Publication number
- MX2009009758A MX2009009758A MX2009009758A MX2009009758A MX2009009758A MX 2009009758 A MX2009009758 A MX 2009009758A MX 2009009758 A MX2009009758 A MX 2009009758A MX 2009009758 A MX2009009758 A MX 2009009758A MX 2009009758 A MX2009009758 A MX 2009009758A
- Authority
- MX
- Mexico
- Prior art keywords
- glycol
- pharmaceutical formulation
- topical pharmaceutical
- ether
- polyhydric alcohol
- Prior art date
Links
- 230000000699 topical effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 abstract 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- 150000005846 sugar alcohols Polymers 0.000 abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 1
- 229960001259 diclofenac Drugs 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 abstract 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición para la aplicación tópica de un NSAID comprende una solución o suspensión del NSAID en un sistema portador que comprende un alcohol polihídrico, un glicol éter y un éster de un ácido graso superior, el sistema portador está presente como una fase sencilla a temperatura ambiente. El NSAID puede ser diclofenaco como ácido de diclofenaco. El alcohol polihídrico puede ser un glicol tal como isopropilenglicol y el glicol éter puede ser éter de dietilénglicol tal como dietilénglicol monoetil éter.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0704846.5A GB0704846D0 (en) | 2007-03-13 | 2007-03-13 | Topical pharmaceutical formulation |
| PCT/GB2008/000540 WO2008110741A2 (en) | 2007-03-13 | 2008-02-15 | Topical pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009009758A true MX2009009758A (es) | 2009-09-24 |
Family
ID=37988913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009009758A MX2009009758A (es) | 2007-03-13 | 2008-02-15 | Formulacion farmaceutica topica. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8541470B2 (es) |
| EP (2) | EP2131813B1 (es) |
| JP (1) | JP2010521442A (es) |
| CN (1) | CN101663022A (es) |
| AU (1) | AU2008224735B2 (es) |
| BR (1) | BRPI0808887A2 (es) |
| CA (1) | CA2680074C (es) |
| CO (1) | CO6220926A2 (es) |
| DK (1) | DK2131813T3 (es) |
| ES (1) | ES2391914T3 (es) |
| GB (1) | GB0704846D0 (es) |
| MX (1) | MX2009009758A (es) |
| MY (1) | MY149545A (es) |
| NZ (1) | NZ579895A (es) |
| PL (1) | PL2131813T3 (es) |
| PT (1) | PT2131813E (es) |
| RU (1) | RU2468794C2 (es) |
| SG (1) | SG179480A1 (es) |
| TW (1) | TWI367110B (es) |
| UA (1) | UA100509C2 (es) |
| WO (1) | WO2008110741A2 (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1882356B (zh) * | 2003-11-20 | 2015-02-25 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
| HRP20150882T1 (hr) | 2008-10-17 | 2015-09-25 | Xenon Pharmaceuticals Inc. | Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| NZ599334A (en) | 2009-10-14 | 2014-03-28 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
| CN102946859B (zh) | 2010-02-26 | 2016-03-02 | 泽农医药公司 | 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途 |
| US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
| US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| KR20150002794A (ko) | 2012-04-12 | 2015-01-07 | 제논 파마슈티칼스 인크. | 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성 |
| HK1217650A1 (zh) * | 2013-01-14 | 2017-01-20 | Infirst Healthcare Limited | 用於治疗剧痛的组合物及方法 |
| AU2014204737B2 (en) * | 2013-01-14 | 2016-08-11 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| JP6474352B2 (ja) * | 2013-02-04 | 2019-02-27 | インファースト ヘルスケア リミテッド | 慢性炎症及び炎症性疾患を治療する組成物と方法 |
| US9012402B1 (en) | 2014-06-11 | 2015-04-21 | James Blanchard | Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation |
| US10561627B2 (en) | 2014-12-31 | 2020-02-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films |
| US11007161B1 (en) | 2014-12-31 | 2021-05-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films |
| US10596117B1 (en) | 2014-12-31 | 2020-03-24 | Eric Morrison | Lipoleosomes as carriers for aromatic amide anesthetic compounds |
| AR103636A1 (es) | 2015-02-05 | 2017-05-24 | Teva Pharmaceuticals Int Gmbh | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |
| GB201502845D0 (en) * | 2015-02-20 | 2015-04-08 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| FR3041534B1 (fr) * | 2015-09-30 | 2019-03-15 | Vetoquinol Sa | Composition de nettoyant auriculaire |
| GB201609968D0 (en) * | 2016-06-07 | 2016-07-20 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| US10100060B2 (en) | 2016-06-16 | 2018-10-16 | Xenon Pharmaceuticals Inc. | Asymmetric synthesis of funapide |
| US20210137829A1 (en) * | 2017-03-07 | 2021-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Topical delivery systems for active compounds |
| US10821075B1 (en) | 2017-07-12 | 2020-11-03 | James Blanchard | Compositions for topical application of a medicaments onto a mammalian body surface |
| EP4360651A3 (en) | 2017-08-24 | 2024-07-17 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| TWI878456B (zh) | 2020-02-18 | 2025-04-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1組成物及其用途 |
| GB2596286B (en) | 2020-06-20 | 2023-01-25 | Francis Davis Adrian | Adherence to topical therapy |
| GB2597526A (en) | 2020-07-27 | 2022-02-02 | Incanthera R&D Ltd | Topical formulation |
| KR20230047375A (ko) | 2020-07-27 | 2023-04-07 | 인칸테라 (알앤디) 리미티드 | 국소 제형 |
| GB202012836D0 (en) | 2020-08-17 | 2020-09-30 | Futura Medical Developments Ltd | Topical composition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06104624B2 (ja) * | 1986-05-07 | 1994-12-21 | 太郎 小木曽 | 経皮吸収剤 |
| PE20011092A1 (es) * | 2000-02-14 | 2001-11-12 | Procter & Gamble | Composiciones para el suministro topico de un agente farmaceuticamente activo que tiene reducida irritacion de la piel |
| DE10019171A1 (de) * | 2000-04-07 | 2001-10-18 | Schering Ag | Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe |
| PE20040321A1 (es) * | 2002-08-22 | 2004-07-15 | Novartis Consumer Health Sa | Composicion topica que comprende diclofenaco |
| US7132452B2 (en) * | 2003-03-10 | 2006-11-07 | Fang-Yu Lee | Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection |
| WO2005027977A2 (en) * | 2003-09-22 | 2005-03-31 | Agis Industries (1983) Ltd. | Diclofenac compositions for the treatment of skin disorders |
| EP1588697A1 (en) | 2004-04-16 | 2005-10-26 | Kurt H. Prof. Dr. Bauer | Emulsion gel for topical application of pharmaceuticals |
| US20050244522A1 (en) | 2004-04-30 | 2005-11-03 | Carrara Dario Norberto R | Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents |
-
2007
- 2007-03-13 GB GBGB0704846.5A patent/GB0704846D0/en not_active Ceased
-
2008
- 2008-02-15 MX MX2009009758A patent/MX2009009758A/es active IP Right Grant
- 2008-02-15 RU RU2009136228/15A patent/RU2468794C2/ru active
- 2008-02-15 NZ NZ579895A patent/NZ579895A/en not_active IP Right Cessation
- 2008-02-15 DK DK08709428.0T patent/DK2131813T3/da active
- 2008-02-15 AU AU2008224735A patent/AU2008224735B2/en not_active Ceased
- 2008-02-15 UA UAA200910111A patent/UA100509C2/ru unknown
- 2008-02-15 PT PT08709428T patent/PT2131813E/pt unknown
- 2008-02-15 MY MYPI20093774A patent/MY149545A/en unknown
- 2008-02-15 PL PL08709428T patent/PL2131813T3/pl unknown
- 2008-02-15 CA CA2680074A patent/CA2680074C/en active Active
- 2008-02-15 CN CN200880007936A patent/CN101663022A/zh active Pending
- 2008-02-15 EP EP08709428A patent/EP2131813B1/en not_active Not-in-force
- 2008-02-15 BR BRPI0808887-0A patent/BRPI0808887A2/pt not_active Application Discontinuation
- 2008-02-15 SG SG2012017497A patent/SG179480A1/en unknown
- 2008-02-15 WO PCT/GB2008/000540 patent/WO2008110741A2/en not_active Ceased
- 2008-02-15 ES ES08709428T patent/ES2391914T3/es active Active
- 2008-02-15 US US12/530,960 patent/US8541470B2/en active Active
- 2008-02-15 EP EP12154983A patent/EP2452671A2/en not_active Withdrawn
- 2008-02-15 JP JP2009553196A patent/JP2010521442A/ja active Pending
- 2008-02-20 TW TW097105840A patent/TWI367110B/zh not_active IP Right Cessation
-
2009
- 2009-10-08 CO CO09111579A patent/CO6220926A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UA100509C2 (ru) | 2013-01-10 |
| TWI367110B (en) | 2012-07-01 |
| ES2391914T3 (es) | 2012-12-03 |
| AU2008224735A1 (en) | 2008-09-18 |
| JP2010521442A (ja) | 2010-06-24 |
| CA2680074C (en) | 2016-07-12 |
| RU2468794C2 (ru) | 2012-12-10 |
| TW200836769A (en) | 2008-09-16 |
| AU2008224735B2 (en) | 2013-04-18 |
| EP2452671A2 (en) | 2012-05-16 |
| CO6220926A2 (es) | 2010-11-19 |
| WO2008110741A8 (en) | 2009-11-19 |
| CA2680074A1 (en) | 2008-09-18 |
| CN101663022A (zh) | 2010-03-03 |
| EP2131813B1 (en) | 2012-08-08 |
| DK2131813T3 (da) | 2012-10-29 |
| PT2131813E (pt) | 2012-10-31 |
| MY149545A (en) | 2013-09-13 |
| GB0704846D0 (en) | 2007-04-18 |
| BRPI0808887A2 (pt) | 2014-09-02 |
| PL2131813T3 (pl) | 2012-11-30 |
| NZ579895A (en) | 2012-02-24 |
| US8541470B2 (en) | 2013-09-24 |
| EP2131813A2 (en) | 2009-12-16 |
| WO2008110741A3 (en) | 2009-03-12 |
| RU2009136228A (ru) | 2011-04-20 |
| WO2008110741A2 (en) | 2008-09-18 |
| US20100099767A1 (en) | 2010-04-22 |
| SG179480A1 (en) | 2012-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009009758A (es) | Formulacion farmaceutica topica. | |
| CY1108700T1 (el) | Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης | |
| BR112012029517A2 (pt) | formulações de fragrância, métodos de fabricação e artigos compreendendo as mesmas. | |
| PL1920759T3 (pl) | Kompozycja kosmetyczna zawierająca fosforan alkilu i eter alkoholu tłuszczowego i glikol polietylenowy, sposoby i zastosowania | |
| GB201009466D0 (en) | System to generate and set up an adverstising campaign based on the insertion of advertising messages within an exchange of messages, | |
| CL2008003910A1 (es) | Formulacion liquida, estable, conteniendo anticuerpo que comprende arginina y metionina; procedimiento para inhibir la deamidacion de moleculas de un anticuerpo que comprende agregar arginina a la formulacion liquida. | |
| IL196169A0 (en) | Bile acid derivatives and pharmaceutical compositions containing the same | |
| WO2013060691A3 (en) | Perfuming compositions and uses thereof | |
| ZA200800818B (en) | Plant support formulation, vehicle for the delivery and translocation of phytologically beneficial substances and compositions containing same | |
| BR112013016662A2 (pt) | composições biodegradáveis para administração de fármaco | |
| WO2013064412A3 (en) | Perfuming compositions and uses thereof | |
| ZA200900206B (en) | Aminophosphoric acid ester derivative and S1P receptor modulator containing the same as active ingredient | |
| MX2009003600A (es) | Composiciones que tienen un compartimiento indicador. | |
| ZA200805714B (en) | Antioxidant compositions useful in biodiesel and other fatty acid and acid ester compositions | |
| EP2277861A4 (en) | CYCLIC AMIN-1-CARBOXYLIC ACID EST DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREWITH | |
| FI20075547L (fi) | Mainosten toimittaminen mobiilissa mainostamisjärjestelmässä | |
| MX340134B (es) | Composiciones portadoras de matriz, métodos y usos. | |
| WO2008045189A3 (en) | Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol | |
| BR112012004916A2 (pt) | composições sns-595 estáveis e métodos de preparação | |
| PL2164941T3 (pl) | Sposób formulacji zapachowych składników aktywnych, dla ich ochrony i wydłużenia czasu ich oddziaływania | |
| PH12013500882A1 (en) | Pharmaceutical compositions | |
| MX2007006908A (es) | Estabilizacion de esteres de glucocorticoides con acidos. | |
| WO2011093831A3 (en) | Effervescent formulations comprising cefprozil as active agent | |
| BRPI0815913A8 (pt) | Composição de misturas antioxidantes apropriadas para uso em biodiesel. | |
| GEP20125563B (en) | 2-amino-2-phenylalkanol derivatives, preparation method thereof and pharmaceutical compositions containing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |